



## Estrone (E1) Test System Product Code: 10325-300

### 1.0 INTRODUCTION

**Intended Use: The Quantitative Determination of Estrone Concentration in Human Serum or Plasma by a Microplate Enzyme Immunoassay, Colorimetric**

### 2.0 SUMMARY AND EXPLANATION OF THE TEST

Estrone, also known as E1, is a steroid hormone (molecular weight of 270.4 daltons) that circulates predominantly protein-bound. In addition to estrone, other natural steroidal estrogens include estradiol, estrinol and their metabolites. Natural estrogens are hormones secreted principally by the ovarian follicles and also by the adrenals, corpus luteum, and placenta in females. In males, estrogens are primarily secreted by the testes. Exogenous estrogens (natural or synthetic) elicit, to varying degrees, all the pharmacologic responses usually produced by endogenous estrogens.

Estrogenic hormones are secreted at varying rates during the menstrual cycle throughout the period of ovarian activity. During pregnancy, the placenta becomes the main source of estrogens. Estrone in young females acts as a minor estrogen with approximately ten (10) times less potency than estradiol.<sup>1</sup> At menopause, ovarian secretion of estrogens declines at varying rates. However, since estrone can also be biosynthesized by adipose tissue via conversion of androstenedione, estrone becomes the primary estrogen in postmenopausal women.<sup>1</sup> Additionally, orally ingested estrogen is metabolized to estrone by the liver through the first-pass effect, which increases endogenous levels of estrone.<sup>1</sup>

In general, males have low levels of serum estrone in comparison to females. Very high levels of estrone in postmenopausal women have been linked to a higher risk of ER-positive breast cancer while younger females with polycystic ovarian syndrome (PCOS) may exhibit high estrone.<sup>2,4</sup>

Estrone determinations have proved of value in a variety of contexts, including the assessment of breast-cancer risk in postmenopausal women and gynecomastia in males. Its principal uses have been in the differential diagnosis of amenorrhea and in the monitoring of ovulation induction.

This kit uses a specific anti-estrone antibody, and does not require prior sample extraction of serum or plasma. Cross-reactivity to other naturally occurring and structurally related steroids is low.


### 3.0 PRINCIPLE

#### Competitive Enzyme Immunoassay (TYPE 5):

The essential reagents required for a solid phase enzyme immunoassay include immobilized antibody, enzyme-antigen conjugate and native antigen.

Upon mixing immobilized antibody, enzyme-antigen conjugate and a serum containing the native antigen, a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of insolubilized binding sites.

The interaction is illustrated by the following equation:



$\text{Ab}_{\text{C.W.}}$  = Monospecific Immobilized Antibody (Constant Quantity)

$\text{Ag}$  = Native Antigen (Variable Quantity)

$\text{EnzAg}$  = Enzyme-antigen Conjugate (Constant Quantity)

$\text{AgAb}_{\text{C.W.}}$  = Antigen-Antibody Complex

$\text{EnzAgAb}_{\text{C.W.}}$  = Enzyme-antigen Conjugate -Antibody Complex

$k_a$  = Rate Constant of Association

$k_d$  = Rate Constant of Disassociation

$K = k_a / k_d$  = Equilibrium Constant

After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

### 4.0 REAGENTS

#### Materials Provided

##### A. Estrone Calibrators – 1ml/vial - Icons A-F

Six (6) vials of serum reference for estradiol at concentrations of 0 (A), 15 (B), 30 (C), 100 (D), 300 (E), 1000 (F) in pg/ml. Store at 2-8°C. A preservative has been added. The calibrators can be expressed in molar concentrations (pmol/L) by multiplying by 3.70.

For example: 1pg/ml x 3.70 = 3.70 pmol/L

##### B. Estrone Enzyme Reagent – 12.0 ml/vial – Icon E

One (1) vial containing Estrone (Analog)-horseradish peroxidase (HRP) conjugate in a protein-stabilizing matrix with dye. Store at 2-8°C.

##### C. Estrone Antibody Coated Plate – 96 wells – Icon Y

One 96-well microplate coated with estrone-specific rabbit IgG and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

##### D. Wash Solution Concentrate – 20ml/vial - Icon D

One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

##### E. Substrate Reagent – 12ml/vial – Icon S

One (1) vial containing tetramethylbenzidine (TMB) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in buffer. Store at 2-8°C.

##### F. Stop Solution – 8ml/vial – Icon T

One (1) vial containing a strong acid (0.5M H<sub>2</sub>SO<sub>4</sub>). Store at 2-8°C.

##### G. Product Instructions.

**Note 1:** Do not use reagents beyond the kit expiration date.

**Note 2:** Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.**

**Note 3:** Above reagents are for a single 96-well microplate.

#### 4.1 Required But Not Provided:

- Pipette capable of delivering 0.025ml (25µl) and 0.050ml (50µl) with a precision of better than 1.5%.
- Dispenser(s) for repetitive deliveries of 0.100ml (100µl) and 0.350ml (350µl) volumes with a precision of better than 1.5%.
- Adjustable volume 0.050ml-1.0ml (50-1000µl) dispenser(s) for conjugate.
- Microplate washer or a squeeze bottle (optional).
- Microplate Reader with 450nm and 620nm wavelength absorbance capability.
- Absorbent Paper for blotting the microplate wells.
- Plastic wrap or microplate cover for incubation steps.
- Vacuum aspirator (optional) for wash steps.
- Timer.
- Quality control materials.

### 5.0 PRECAUTIONS

#### For In Vitro Diagnostic Use

**Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

**Safe Disposal of kit components must be according to local regulatory and statutory requirement.**

### 6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood, serum or heparinized plasma in type, and taken with the usual precautions in the collection of venipuncture samples. For accurate comparison to establish normal values, a fasting morning serum sample should be obtained. The blood should be collected in a redtop (with or without gel additives) venipuncture tube(s) or for plasma use evacuated tube(s) containing heparin. Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum or plasma from the cells.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.050ml (50µl) of the specimen is required.

### 7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and high range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

### 8.0 REAGENT PREPARATION

#### 1. Wash Buffer

Dilute contents of wash solution concentrate to 1000ml with distilled or deionized water in a suitable storage container. Diluted buffer can be stored at 2-30°C for up to 60 days.

**Note: Do not use reagents that are contaminated or have bacteria growth.**

### 9.0 TEST PROCEDURE

*Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20 - 27°C).*

**\*\*Test Procedure should be performed by a skilled individual or trained professional\*\***

- Format the microplates' wells for each serum reference, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
- Pipette 0.025 ml (25 µL) of the appropriate serum reference, control or specimen into the assigned well.
- Add 0.100 ml (100µl) of the Estrone Enzyme Reagent to all wells.
- Swirl the microplate gently for 20-30 seconds to mix.
- Cover and incubate for 45 minutes at room temperature.

- Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
- Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
- Add 0.100 ml (100µl) of substrate solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells.**
- DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION**
- Incubate at room temperature for twenty (20) minutes.
- Add 0.050ml (50µl) of stop solution to each well and gently mix for 15-20 seconds. **Always add reagents in the same order to minimize reaction time differences between wells.**
- Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm). **The results should be read within fifteen (15) minutes of adding the stop solution.**

**Note:** Dilute the samples suspected of concentrations higher than 1000pg/ml 1:5 and 1:10 with estrone '0' pg/ml calibrator or male patient serum pools with a known low value for estrone.

### 10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of estrone in unknown specimens.


- Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
- Plot the absorbance for each duplicate serum reference versus the corresponding estradiol concentration in pg/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
- Connect the points with a best-fit curve.
- To determine the concentration of estrone for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in pg/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.323) intersects the dose response curve at (43.1pg/ml) estrone concentration (See Figure 1).

**Note:** Computer data reduction software designed for ELISA assay may also be used for the data reduction. **If such software is utilized, the validation of the software should be ascertained.**

EXAMPLE 1

Sample I.D.	Well Number	Abs (A)	Mean Abs (B)	Value (pg/ml)
Cal A	A1	2.206	2.169	0
	B1	2.136		
Cal B	C1	1.866	1.866	15
	D1	1.866		
Cal C	E1	1.503	1.516	30
	F1	1.530		
Cal D	G1	0.890	0.903	100
	H1	0.917		
Cal E	A2	0.502	0.498	300
	B2	0.495		
Cal F	C2	0.293	0.299	1000
	D2	0.306		
Pat# 1	E2	1.325	1.323	43.1
	F2	1.320		

\*The above table and data below is for example only. Do not use it for calculating your results.



Note: Multiply the horizontal values by 1000 to convert into pg/ml.

## 11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

1. The absorbance (OD) of calibrator 0 pg/ml should be  $\geq 1.3$ .
2. Four out of six quality control pools should be within the established ranges.

## 12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.

### 12.1 Assay Performance

1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
6. Plate readers measure vertically. Do not touch the bottom of the wells.
7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
8. Use components from the same lot. No intermixing of reagents from different batches.
9. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind's IFU may yield inaccurate results.
10. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
11. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
12. Risk Analysis- as required by CE Mark IVD Directive 98/79/EC- for this and other devices, made by Monobind, can be requested via email from [Monobind@monobind.com](mailto:Monobind@monobind.com).

### 12.2 Interpretation

1. **Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. The reagents for the procedure have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays. (Boscato LM, Stuart MC. *Heterophilic antibodies: a problem for all immunoassays* Clin. Chem 1988;34:27-33). For diagnostic purposes the results from this assay should be used in combination with clinical examination, patient's history, and, all other clinical findings.

4. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
5. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
6. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.

## 13.0 EXPECTED RANGES OF VALUES

In agreement with established reference intervals for a "normal" adult population and females during gestation, the expected ranges for the Estrone AccuBind® ELISA Test System are detailed in Table 1.

TABLE 1  
Expected Values for the Estradiol Test System

	Median	Range
<b>Females</b>	-	-
Age 20-49	20	6-400
Age 50-69	10	ND-26
Age 70+	19	ND-104
<b>Male Adults</b>	21	ND-54

It is important to keep in mind that establishment of a range of values, which can be expected to be found by a given method for a population of "normal" persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons, each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

## 14.0 PERFORMANCE CHARACTERISTICS

### 14.1 Precision

The within and between assay precision of the Estrone AccuBind® ELISA Test System were determined by analyses on six different levels of pool control sera. The number, mean values, standard deviation and coefficient of variation for each of these control sera are presented in Table 2 and Table 3.

TABLE 2  
Precision data for the Estrone Test System

	Mean Value (pg/ml)	Within-Run Precision		Total Precision (n=80)	
		SD	CV%	SD	CV%
Sample 1	23.508	1.36	5.74	2.64	11.11
Sample 2	38.114	1.22	3.03	4.59	11.39
Sample 3	103.239	6.14	6.25	9.61	9.79
Sample 4	219.433	4.96	2.18	11.81	5.19
Sample 5	606.769	20.31	3.47	35.55	6.07
Sample 6	777.688	28.08	3.84	54.69	7.47

\*As measured in forty experiments in duplicate over a twenty day period.


### 14.2 Sensitivity

The Estrone AccuBind® Test System has a LoB of 6.03 pg/ml and a LoD of 10.68 pg/ml.

### 14.3 Accuracy

#### 14.3.1 Linearity

The linearity of the Estrone AccuBind® ELISA Test System was tested by diluting a human serum samples containing a high level of Estrone (~1400 pg/ml) with the "0 pg/ml" serum reference. The system was determined to have excellent linearity up to 1400pg/ml with a slope of 1.035 and a correlation factor of 0.992. The expected values were compared to the observed concentrations of the samples and graphed in Figure 2.



### 14.3.2 Recovery

The recovery of the Estrone AccuBind® ELISA Test System was calculated for five patient samples spiked with 25, 50, 250, 500, and 800 pg/ml estrone. Recoveries were determined to be within 15% of the expected values for all samples.

### 14.3.3 Method Comparison

The Estrone AccuBind® ELISA Test System was compared with a chemiluminescent assay. Biological specimens from low, normal and relatively high aldosterone level populations were used (The values ranged from 10 pg/ml – 850 pg/ml). The total number of such specimens was 68. The least square regression equation and the correlation coefficient were computed for this estrone ELISA in comparison with the reference method. The data obtained is displayed in Table 3.

Method	TABLE 3		
	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
Monobind (y)	98.85	y = 0.855x + 9.063	0.988
Reference (x)	105.0		

Only slight amounts of bias between this method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

### 14.4 Specificity

The % cross reactivity of the estradiol antibody to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between dose of interfering substance to dose of estradiol needed to displace the same amount of labeled analog.

Substance	Cross Reactivity
Estradiol 17β	0.8282
Estradiol 17α	0.2107
Estrilol	0.0347
Progesterone	0.0056
DHEA sulfate	0.0017

## 15.0 REFERENCES

1. Ruggiero RJ, Likis FE, "Estrogen: Physiology, Pharmacology, and Formulations for Replacement Therapy", *Journal of Midwifery & Women's Health*; 47:130-138 (2002).
2. Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Shinzaburo N. "Association of Serum Estrone Levels with Estrogen Positive Breast Cancer Risk in Postmenopausal Japanese Women", *Clinical Cancer Research*; 9:2229-2233 (2003).
3. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M, Maloche C. "Concentrations of Estrone, Estradiol, and Estrone Sulfate and Evaluation of Sulfatase and Aromatase Activities in Pre- and Postmenopausal Breast Cancer Patients", *J. Clinical Endocrinology and Metabolism*; 81:1460-1464 (1996).
4. Chang RJ, Mandel FP, Lu JKH, Judd HL; Enhanced Disparity of Gonadotropin Secretion by Estrone in Women with Polycystic Ovarian Disease, *The Journal of Clinical Endocrinology & Metabolism*, 54:490-494 (1982) <https://doi.org/10.1210/jcem-54-3-490>
5. Abraham, G.E. "The application of natural steroid radioimmunoassay to gynecologic endocrinology". In: Abraham, G.E. (Ed.) *Radioassay Systems in Clinical Endocrinology*, Marcel Dekker, Basael: 475-529 (1981).
6. Batzer F, "Hormonal evaluation of early pregnancy", *Fertility Sterility*, 34:1-13 (1980).

7. Bauman J, "Basal body temperature: unreliable method of ovulation detection", *Fertility Sterility*, 36:729-33 (1981).
8. Gautray JP, et al. "Clinical investigation of the menstrual cycle: clinical, endometrial and endocrine aspects of luteal defects", *Fertility Sterility*, 35:296-303 (1981).
9. Hensleigh PA, Fainstat T, "Corpus luteum dysfunction: serum progesterone levels in diagnosis and assessment of therapy for recurrent and threatened abortion", *Fertility Sterility*, 32:396-9 (1979).
10. Hernandez JL, et al, "Direct evidence of luteal insufficiency in women with habitual abortion", *Obstetric Gynecology*, 49:705-8 (1977).
11. Goldstein D, et al, "Correlation between Estradiol and Progesterone in cycles with luteal phase deficiency", *Fertility Sterility*, 37:348-54 (1982).
12. Klopper A, Fuchs F, Progestagens. In: Fuchs F, Klopper A, editors. *Endocrinology of Pregnancy*. Hagerstown: Harper & Row, 99-122 (1977).
13. Lehmann F, Bettendorf G, "The endocrine shift from a normal cycle to anovulation", In: Insler V, Bettendorf G, editors. *Advances in Diagnosis and Treatment of Infertility*. Amsterdam: Elsevier/North Holland, 105-13 (1981).
14. Tietz, *Textbook of clinical chemistry*, 2nd ed. Philadelphia: W.B. Saunders, (1994).

Effective Date: 2018-Nov-21 Rev. 0  
MP10325

DCO: N/A  
Product Code: 10325-300

Size	96(A)	192(B)
Reagent (µl)	A) 1ml set	1ml set
	B) 1 (12ml)	2 (12ml)
	C) 1 plate	2 plates
	D) 1 (20ml)	1 (20ml)
	E) 1 (12ml)	2 (12ml)
	F) 1 (8ml)	2 (8ml)

For Orders and Inquires, please contact


**Monobind Inc.**  
100 North Pointe Drive  
Lake Forest, CA 92630 USA

Tel: +1 949.951.2655 Mail: [Info@monobind.com](mailto:Info@monobind.com)  
Fax: +1 949.951.3539 Fax: [www.monobind.com](http://www.monobind.com)



Please visit our website to learn more about our products and services.

## Glossary of Symbols (EN 980/ISO 15223)



**EC REP**  
Authorized Rep in European Country

**CE**  
European Conformity